Otsuka Wins FDA Approval for Groundbreaking ADHD Drug Simtriyo

In July 2026, the U.S. FDA approved Otsuka Pharmaceutical's Simtriyo (centanafadine), marking the first-ever norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for ADHD patients aged 6 and older weighing at least 20 kg, and offering a new, non-stimulant treatment approach supported by four pivotal Phase 3 trials and expected to be available later this year following DEA scheduling.

First-in-Class Simtriyo Set to Shake Up the ADHD Treatment Market

The FDA has approved Otsuka Pharmaceuticals once-daily extended-release capsule Simtriyo (centanafadine) for ADHD in patients aged 6 and older and is expected to become a significant player in a large and under-penetrated market. Before launching in the U.S., Simtriyo must pass a controlled-substance review by the DEA. Its classification could influence its market potential; if classified similarly to Schedule II drugs like Adderall, it could face restrictions, whereas a lower classification might improve its competitiveness.

Simtriyo is recognized as a stimulant due to its dopaminergic effects by increasing neurotransmitter availability in attention pathways. ADHD impacts around 7 million children and 15.5 million adults in the U.S. Although stimulants are popular for treatment, many patients switch due to side effects and varying effectiveness. The Jefferies team remarked that the market is focusing on multiple treatment classes and believes Simtriyo has an opportunity to expand the overall non-stimulant segment rather than simply take share from existing products such as Qelbree or Strattera. 

Otsuka aims for peak sales exceeding 100 billion Japanese yen (USD 610 million) following its acquisition of Neurovance, which developed the drug. Simtriyo showed significant improvement in ADHD symptoms in four phase 3 trials, with some common side effects being rash and decreased appetite.

Lenard Adler, a director at NYU Langone Health, emphasized that Simtriyo introduces a novel mechanism, expanding treatment options for the individualized nature of ADHD. The approval follows a recent setback for another Otsuka drug, Rexulti, which faced FDA rejection for PTSD. With this approval, Otsuka broadens its CNS portfolio and can tap into a broad prescriber base for ADHD, leveraging its existing commercial infrastructure.

Impact on the Healthcare Industry

The approval of Simtriyo impacts the healthcare industry by introducing the first-in-class NDSRI for ADHD and addressing this need by targeting three neurotransmitter pathways simultaneously and offering early and customizable efficacy for diverse patient populations.

This new treatment positively impacts the healthcare industry through a unique triple-reuptake mechanism targeting norepinephrine, dopamine, and serotonin, while expanding options for patients aged 6 and older and showing symptom reduction by one week. It overcomes past limitations by treating complex neurodevelopmental profiles and fitting easily into daily clinical routines as an extended-release capsule. By addressing patient heterogeneity and tolerability challenges tied to older single-target drugs, this therapy overall improves real-world care options. Its once-daily oral design supports broad community access and makes implementation straightforward for standard medical providers.

Impact of the CNS Clinical Trials Industry

The global CNS clinical trials market size was calculated at USD 8.65 billion in 2025 and is predicted to increase from USD 9.33 billion in 2026 to approximately USD 18.49 billion by 2035, expanding at a CAGR of 7.90% from 2026 to 2035.

According to Precedence Research, this approval transforms the industry by introducing the first approved triple reuptake inhibitor and addressing critical industry hurdles by offering broad efficacy across four Phase III trials and expanding into complex overlapping conditions like anxiety.

These triple-action therapies targeting norepinephrine, dopamine, and serotonin validate complex multi-mechanism approaches and broader trial designs. They prove that multi-neurotransmitter targets work for neurodevelopmental conditions from pediatric ages, and set a new standard for studying wide-ranging mental health issues. These trials expand future research by shifting study goals past basic symptoms by measuring profound living skills including executive function and overlapping anxiety conditions across diverse patient populations.

This further addresses industry challenges by introducing a triple-action mechanism for ADHD heterogeneity, like Otsuka's trials for comorbid anxiety, and achieving statistical separation from placebos by week one. These treatments also address previous challenges like single neurotransmitter focus, messy real-world patient overlap, and subjective measurement noise on rating scales like AISRS and ADHD-RS-5.

About Otsuka Pharmaceutical

Otsuka Pharmaceutical is a global healthcare company founded in Japan in 1921. Otsuka focuses on severe medical needs and everyday wellness through its pharmaceuticals and nutraceuticals. The pharmaceutical division targets psychiatry, neurology, oncology, and rare diseases alongside medical devices, while the consumer health division offers science-based wellness products like Pocari Sweat and Nature Made.

The company aims to be an indispensable global health contributor by creating original, evidence-based solutions. Instead of competing on price, Otsuka emphasized total physical, mental, and social well-being to address changing health challenges across all stages of life.